Market Place
Sourcing Support
X4 Pharma’s Mavorixafor MAA Validated By EMA For WHIM Syndrome
24 Jan 2025 //
GLOBENEWSWIRE
X4 Pharma Announces EMA Validation of MAA for Mavorixafor
24 Jan 2025 //
PR NEWSWIRE
X4 Pharma, Norgine To Commercialize Mavorixafor In Europe & ANZ
13 Jan 2025 //
GLOBENEWSWIRE
X4 Pharma Presents Mavorixafor Ph 3 Trial at ASH Meeting
04 Dec 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Dec 2024 //
GLOBENEWSWIRE
X4 Pharma to Participate in Piper Sandler Healthcare Conference
26 Nov 2024 //
GLOBENEWSWIRE
X4 Pharma to Participate in Stifel 2024 Healthcare Conference
14 Nov 2024 //
GLOBENEWSWIRE
X4 Pharma Reports Positive Phase 2 Results in Chronic Neutropenia
13 Nov 2024 //
GLOBENEWSWIRE
X4 Pharma Reports Q3 2024 Financial Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals To Report Q3 Results And Phase 2 Data
24 Oct 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule
01 Oct 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Sep 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Q2 2024 Results And Corporate Updates
08 Aug 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces Inducement Grants
01 Aug 2024 //
GLOBENEWSWIRE
Orchestra BioMed Appoints John Mack To Board Of Directors
30 Jul 2024 //
GLOBENEWSWIRE
X4 Pharma Announces +ve Data from Ongoing Six-Month Ph2 Trial of Mavorixafor
27 Jun 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Nasdaq Employee Inducement Grants
03 Jun 2024 //
GLOBENEWSWIRE
X4 Pharma Investor Event On New Mavorixafor Chronic Neutropenia Data
29 May 2024 //
GLOBENEWSWIRE
X4 Pharma To Participate In H.C. Wainwright BioConnect Investor Conference
13 May 2024 //
GLOBENEWSWIRE
X4 Pharma $125M From Voucher Sale, Loan Drawdown
09 May 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Q1 2024 Results And Updates
07 May 2024 //
GLOBENEWSWIRE
X4 Pharma: Inducement Grants Under Nasdaq Rule 5635(c)(4)
01 May 2024 //
GLOBENEWSWIRE
X4 Pharma Q1 2024 Results & Call on May 7
30 Apr 2024 //
GLOBENEWSWIRE
X4 enters commercial fold with FDA approval of rare disease drug Xolremdi
30 Apr 2024 //
FIERCE PHARMA
PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution
29 Apr 2024 //
PR NEWSWIRE
X4 Pharma`s XOLREMDI™ Approved by FDA for WHIM Syndrome
29 Apr 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
01 Apr 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial
09 Dec 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Dec 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
10 Nov 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review for Mavorixafor
31 Oct 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces Appointment of R. Keith Woods to Board of Directors
18 Oct 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Oct 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
X4 Pharma to Participate in the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Submission of NDA to U.S. FDA for Mavorixafor
05 Sep 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as CMO
08 Aug 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
03 Aug 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
30 Jun 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Expected to Join Russell 3000® Index
13 Jun 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
GLOBENEWSWIRE
X4 touts more positive PhIII data for its WHIM syndrome treatment
17 May 2023 //
ENDPTS
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
16 May 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor
16 May 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports First-Quarter 2023 FYR & &s Corporate Update
04 May 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals to Report First-Quarter 2023FYR and Host a Conference Call
26 Apr 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Late-Breaking Abstract of WHIM Phase 3 Data Accepted
12 Apr 2023 //
GLOBENEWSWIRE
X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
GLOBENEWSWIRE
